Research on PTP1B inhibitors as potential therapeutic options for the treatment of DM and obesity has reached a peak, as approximately 300 PTP1B inhibitors have been developed from a variety of natural sources, with the largest representation from flavonoids [11,39]. This evidence concerns the gene PTPN1 and obesity due to melanocortin 4 receptor deficiency.